Patients with baseline age ≥70 years, ECOG >0, primary lung cancer, aCharlson index >2 and/or receiving non-adjuvant ICI therapy had significantly higher pre-ICI IL-6 levels. This evidence concerns the gene IL6 and lung cancer.